RLMD
$33.06
Relmada Therapeutics
$.17
.52%
RLMD
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.85)
Revenue:  $0.00 Mil
Wednesday
Nov 11
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when RLMD reports earnings?
Beat
Meet
Miss

Where is RLMD's stock price going from here?
Up
Flat
Down
Stock chart of RLMD
Analysts
Summary of analysts' recommendations for RLMD
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.